TRUSELTIQ (infigratinib), FDA Approved for Treatment of Cholangiocarcinoma, Available at Biologics by McKesson
CARY, N.C., June 21, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by QED Therapeutics, an affiliate of BridgeBio Pharma, Inc. (BridgeBio) and Helsinn Group, as a specialty pharmacy provider for TRUSELTIQTM (infigrati...
Source: McKesson News - Category: Information Technology Source Type: news
More News: Bile Duct Cancer | Cancer & Oncology | Cholangiocarcinoma | Information Technology | Pharmaceuticals | Rare Diseases